Efficacy Analysis of Fluticasone Propionate Nebulized Inhalation in the Treatment of Cough Variant Asthma in Chil-dren
Objective:To explore and analyze the efficacy of montelukast sodium combined with fluticasone propionate nebulized inhalation in the treatment of children with cough variant asthma.Methods:74 children with cough variant asthma admitted to Jiangdu People's Hospital in Yangzhou City for treatment were collected for the study from January 2021 to December 2022.The children were divided into two groups by random drawing,with 37 cases in each group.The control group was treated with nebulized inhalation of fluticasone propionate,while the study group was treated with montelukast sodium chewable tablets.Both the study group and the control group were treated and observed for 12 weeks,and the prognosis of the children was recorded.Results:After 12 weeks of treatment,a total of 36 cases(97.30％)in the study group met the effective treatment criteria,while the control group had only 30 cases(81.08％).The total effective rate of the study group was more prominent and better than that of the control group(x2=5.045,P＜0.05).The daytime and nighttime cough symptom scores of the study group after 12 weeks of treatment were also significantly lower than those of the control group(t=25.927,10.976;P＜0.05).The maximum expiratory flow rate and forced expiratory volume in the first second after 12 weeks of treatment in both groups were higher than before treatment(t=5.542,8.324;P＜0.05).The incidence of adverse reactions,such as headache,abdominal pain,dizziness,and hoarseness during the 12 cycles of treatment in the study group was 5.41％,compared with 10.81％in the control group.There was no difference between the study group and the control group(x2=4.163,P＞0.05).Conclusion:The combination of montelukast sodium and fluticasone propionate nebulized inhalation can improve the treatment effect,alleviate daytime and nighttime cough symptoms,and improve lung function in children with cough variant asthma,with relatively high safety.
万方数据
维普
